Table 5.
Overall Survival (OS) and Event Free Survival(EFS) and Their Relations to the Prognostic Factors
| OS | EFS | ||||
|---|---|---|---|---|---|
| Clinicopathological variables in Whole group | No. | No. of events | p-value | No.of events | P-value |
| 50 | 10 | - | 12 | - | |
| Age groups | |||||
| ≤ 50 years | 30 | 4 | 0.184 | 6 | 0.536 |
| > 50 years | 20 | 6 | 6 | ||
| Menopausal status | |||||
| Post | 30 | 7 | 0.608 | 9 | 0.326 |
| Pre | 20 | 3 | 3 | ||
| Family history | |||||
| Negative | 44 | 8 | 0.484 | 10 | 0.471 |
| Positive | 6 | 2 | 2 | ||
| Tumor size | |||||
| ≤5cm(T1&T2) | 44 | 9 | 0.727 | 12 | 0.185 |
| ≤5cm(T3&T4) | 6 | 1 | 0 | ||
| Lymph nodes status: | |||||
| Negative | 18 | 1 | 0.097 | 4 | 0.723 |
| Positive | 32 | 9 | 8 | ||
| Tumor stage | 33 | 5 | 33 | ||
| I&II | 17 | 5 | 0.222 | 17 | 0.862 |
| III | |||||
| Tumor grade | 11 | 0.034 | |||
| G1&G2 | 33 | 9 | 0.063 | 1 | |
| G3 | 17 | 1 | |||
| Ki-67 LI | 1 | 0.586 | |||
| ≥20% | 44 | 10 | 0.148 | 11 | |
| <20% | 6 | 0 | |||
| Radiotherapy | |||||
| No | 26 | 8 | 0.03 | 8 | 0.135 |
| yes | 24 | 2 | 4 | ||
| Chemotherapy | |||||
| Anthracycline & Taxane | 36 | 5 | 0.212 | 6 | 0.104 |
| Anthracycline only | 14 | 5 | 6 | ||
| TOP2A gene status: | 1 | ||||
| Amplified | 5 | 1 | 1 | 0.984 | |
| Deleted | 4 | 0 | * | 10 | |
| Normal | 41 | 9 | |||
| TOP2A gene status | 10 | 0.873 | |||
| Normal | 41 | 9 | 0.524 | 2 | |
| Abnormal | 9 | 1 | |||
| CEP 17 chromosome: | 11 | 0.456 | |||
| Normal | 43 | 10 | 0.193 | 1 | |
| Polysomy | 7 | 0 | |||
| Disease status: | 0.729 | ||||
| Not advanced | 22 | 1 | 0.034 | 5 | |
| Locally advanced | 28 | 9 | 7 | ||
| TOP2A&CEP 17 combined: | 2 | 0.697 | |||
| Abnormal | 10 | 1 | 0.369 | 10 | |
| Normal | 40 | 9 | |||
*
P value cannot be calculated due to small sample size